Neuren responds to social media commentary regarding Rett Syndrome trial

**Australia, 5 August 2013:** Neuren Pharmaceuticals Limited (ASX:NEU) has been made aware of comments posted on a third party website concerning the Company’s Phase 2 clinical trial of NNZ-2566 in adolescents and adults with Rett Syndrome. It appears that parents of subjects participating in the trial have suggested that certain of the symptoms that their daughters experience have improved during participation in the trial. The Company would like to assure the market that these comments reflect subjective impressions that have not been validated by analysis of clinical data. In particular, we would like to reiterate that, as the study is a randomized, double-blind trial, neither Neuren, the clinical investigators nor the parents can be or are aware of the treatment assignment (NNZ-2566 or placebo) for any subject. To the best of our knowledge, the blinded nature of the trial has not been compromised. The clinical benefit, if any, of NNZ-2566 compared to placebo will not be known until treatment assignment is unblinded and the trial data are analysed. Neuren will communicate the results of that analysis when it has been completed and reviewed by the appropriate parties, which is anticipated to be in the second half of 2014.

*Forward-looking Statements*

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.

*About Neuren*

Neuren Pharmaceuticals Limited (Neuren) is a publicly listed biopharmaceutical company focusing on the development of new therapies for brain injury, neurodevelopmental and neurodegenerative disorders. The novel drugs target chronic conditions such as Rett Syndrome and Fragile-X Syndrome as well as acute neurological injuries. Neuren presently has a clinical-stage molecule, NNZ-2566 in two Phase 2 clinical trials as well as NNZ-2591 in pre-clinical development. Neuren currently has operations in New Zealand, Australia and the United States.

*For more information, please contact:*

Larry Glass, CEO
lglass@neurenpharma.com
Tel: +1 301 941 1830

Dr Richard Treagus, Executive Chairman
rtreagus@neurenpharma.com
Tel: +61 417 520 509